The anterior pituitary is itself under hypothalamic control and this is med¬ iated by the various 'releasing factors' and the portal-hypophysial circulation. The hypothalamus can be influenced by impulses from higher centres. Its activity can also be modified by the ovarian sex steroids, themselves the result of gonadotrophic activity. An ovarian-pituitary 'feed-back' mechanism there¬ fore exists which forms the basis of cyclical pituitary-ovarian function, ovula¬ tion and menstruation. A detailed consideration of these topics, while relevant, is beyond the scope of this article.
It is proposed to limit this account to a brief review of gonadotrophin pre¬ parations which have been used clinically and then to concentrate on those extracts made from human sources, particularly the hypophysis. In doing so it is a great privilege to join in a tribute to Bernhard Zondek who was instru¬ mental in setting off the chain reaction which has led to our current knowledge and problems in the field of human gonadotrophins.
GONADOTROPHIN PREPARATIONS IN CLINICAL USE FOLLICLE STIMULATING SUBSTANCES

Animal origin
Pregnant mare's serum (pms), bovine, ovine and porcine pituitaries con¬ stitute the main sources of extracts containing follicle-stimulating activity. These substances, alone or in combination with human chorionic gonado¬ trophin (hcg) have received extensive clinical trial. The fact that Müller (1962) was able to collect thirty-nine reported cases of 'hyperstimulation syndrome' between 1942 and 1961 certainly indicates that this form of therapy was not without effect on human ovaries. In terms of induced ovulation, however, the results obtained showed a lack of consistency (see Kotz & Herrmann, 1961) and treatment with animal hormones has now been largely abandoned.
There are many possible explanations for these early failures. Rigid criteria were not always used in the selection of cases. There was a lack of adequate controls. No uniformity in dosages or methods of administration existed. But probably most important of all were interference from antibodies to fsh from animal sources (see Ostergaard, 1964) and problems of species specificity. Not until these obstacles were removed was the way clear for encouraging and reproducing results with induced ovulation.
Human origin
In 1958 an fsh extract obtained from human pituitaries was tested on seven patients (Gemzell, Diczfalusy & Tillinger, 1958) . There was little doubt about its ability to stimulate the development of Graafian follicles and, with hcg treatment, to lead to ovulation and corpus luteum formation. Since then these effects have been repeatedly confirmed Bettendorf, 1962 Bettendorf, , 1963 Bettendorf, , 1964 Buxton, 1961; Buxton & Herrmann, 1960 Buxton, Käse & Van Orden, 1963; Crooke, 1964; Crooke, Butt, Palmer, Morris, Edwards & Anson, 1963a; Crooke, Butt, Palmer, Morris, Edwards, Taylor & Short, 1963b; Carrington, Morris, Palmer & Edwards, 1964a; Crooke, Butt, Palmer, Bertrand, Carrington, Edwards & Anson, 1964b; Crooke, Butt, Palmer, Morris & Morgan, 1964c; Diczfalusy, Johannison, Tillinger & Bettendorf, 1964; Gemzell, 1961 Gemzell, , 1962a Gemzell, , b, 1963a Gemzell, , b, c, 1964 Gemzell, , 1965a Gemzell, Diczfalusy & Tillinger, 1960; Gemzell & Roos, 1966a, b; Grant, Meares, Ferguson & Wallace, 1964; Rosemberg, Coleman, Gibree & MacGillivray, 1962 (Zondek, 1931) . Fluhman (1929) and Zondek (1930) separately described a gonadotrophic substance in the blood and urine of menopausal women which caused follicular development in experimental animals. Not until 1960 did Lunenfeld, Menzi & Volet (1960) report that gonadotrophins extracted from human post-meno¬ pausal urine could stimulate human ovaries. Numerous subsequent publica¬ tions have supported this observation and have shown that human menopausal gonadotrophin (hmg) and hcg can induce ovulation (Borth, Lunenfeld & Menzi 1961a; Crooke et al., 1963a Crooke et al., , 1964b Diczfalusy et al., 1964; Lunenfeld, 1963 Lunenfeld, , 1965 Lunenfeld, Rabau, Rumney, Winkelsberg, 1961; Lunenfeld, Sulimovici & Rabau, 1962; Palmer & Dorangeon, 1962; Pasetto & Montanino, 1964a, b; Rosemberg, Coleman, Demany & Celso-Ramon, 1963; Rosemberg, Maher, Stern & Demany, 1964; Staemmler, 1961; Vande Wiele & Turksoy, 1965) . The preparation in common use today is 'PergonaP (Instituto Farmacologico Serono, Rome) and the method of its extraction has been evolved by Donini and collaborators (Donini, Puzzuoli & Montezemolo, 1964 Hypophysectomized rat prostate assay (Loraine & Brown, 1954) Ovarian ascorbic acid depletion (Parlow, 1961) Seminal vesicle test in immature intact male rats (Van Hell et al., 1964) Immunological reaction (Wide et al., 1961; Wide & Gemzell, 1962) 1st . The ratio of fsh to lh could be of importance (Diczfalusy et al., 1964) . Assuming that the fsh and lh contents of any preparations used should be known, the chance of any two workers using the same assay combination is theoretically only 1 in 160. Even with the same assay combination, significant differences in experimental design, statistical evaluation and the strains of animal used may exist.
Such factors constitute major obstacles to valid comparisons between one treatment schedule and another. Ideally, all preparations should be assayed by the same tests in the same laboratory using the same standards. In practice, one has to be content with conversion tables. The first column in Table 2 gives the Table 2 ovarian augmentation assay for fsh activity (1) The correlation factor relates the amounts of the various reference preparations which are equipotent in the ovarian augmentation assay. The higher the correlation factor, the lower the potency of the preparation.
(2) The activity ratios between nih-fsh-s I/nih-fsh-s2 and nih-fsh-s3 are 1-0/0-87 and 1-1 (National Institutes of Health data).
(3) The data for this (1962) and Borth et al. (1961) and the description accom¬ panying ampoules of nih-hpg-upmi. approximate correlation factors between reference materials which have been or could be used in the measurement of fsh activity by the ovarian augmenta¬ tion assay. The calculations were based on data given by Butt, Crooke & Wolf (1965) , Rosemberg, Engel & Lewis (1962) and Borth, Lunenfeld & Menzi (1961b) , and the description which accompanies vials ofNiH-HPG-uPMi. Recently an international unit (i.u.) for fsh activity has been established and the third column of Table 2 gives the strength per mg of various reference preparations in such units. Table 3 shows the correlation factors between some of the reference prepara¬ tions for lh obtained from data given by Butt et al. (1965) and Reichert (1965) . (Loraine & Brown, 1954; Wide & Gemzell, 1962) was about 25 i.u. of HCG/mg. During the last few years at Uppsala, the preparation described above has (1965) . been replaced by a product obtained from whole frozen pituitaries. The gonadotrophins were extracted according to the first step of a procedure developed by Roos for the isolation of pure fsh (Roos & Gemzell, 1964 (Butt, Crooke & Cunningham, 1961) . Three products of different purity were used clinically (Crooke, 1964; Crooke et al., 1963a Crooke et al., , 1964a (Gemzell, 1965b (Crooke et al., 1963b; Edwards, 1964; Gemzell, 1963c Gemzell, , 1965b Mahesh & Greenblatt, 1961 ( 1955) and Klopper (1957) suggests that a single follicle and corpus luteum are associated with a maximum total oestrogen excretion of 100 µg and a peak pregnanediol output of 5 mg in 24-hr specimens of urine from the follicular and luteal phases of the menstrual cycle respectively. Theoretically, the sex steroid excretion pattern should give an accurate picture of ovarian activity.
Various reservations must, however, be made. It has been pointed out, for example, that excessively numerous unruptured follicles additively produce as much oestrogen and progesterone as a normal corpus luteum (Buxton et al., 1963 (Johannison, Gemzell & Diczfalusy, 1961) . The simplicity and speed of these tests make them a worth-while source of information.
The consistency and volume of cervical mucus give some help in assessing follicular development. The arborization pattern is sometimes used in the detection of ovulation. The mechanism and significance of these tests has been discussed by Zondek (1954 (Lunenfeld, 1965; Vande Wiele & Turksoy, 1965) and its arborization pattern (David, Insler & Ber, 1964) as measures of follicular development. hcg is usually given after the follicles have been primed with fsh in amounts between 9000 and 45,000 i.u. over 1 to 6 days. Ovulation may also occur without the addition of hcg (Bettendorf, 1962 (Bettendorf, , 1963 (Bettendorf, , 1964 . The original claim that this avoided overstimulation has not been substantiated.
Timing of fsh and hcg administration
This has been extensively investigated by Crooke et al. (1963a Crooke et al. ( , 1964b using experiments of statistical design on a series of nine patients. With patients of steroid excretion as their criteria, they considered that the most normal response was likely to occur when the fsh is divided into three equal doses over 8 days and hcg is given as a single injection after an interval of under 96 hr after the third dose.
The timing of treatment has also been assessed here with predictability of ovulation, the number of treatments required before conception (the 'treatment/ pregnancy' ratio) and the proportion of patients treated who conceived (the 'patient/success' ratio) as the measures of success. Daily hpfsh for 10 days, followed 24 to 48 hr later by hcg for 3 days gave the best results. The frequency of multiple births was high, but the 'treatment/pregnancy' and 'patient/ success' ratios were both around 2 (Gemzell & Roos, 1966a) . hpfsh administra¬ tion for 4 to 6 days with a gap of 2 to 3 days before hcg gave lower levels of total oestrogen excretion but the pregnancy rate seemed to fall and the time of ovulation became less predictable, hpfsh and hcg given together from the onset of treatment appeared to have the same effect.
It has been suggested that the timing of hcg should depend on the vaginal smears, studies of cervical mucus and the results of post-coital tests (Vande Wiele & Turksoy, 1965) . At the present time it seems unlikely that booster doses of hcg are necessary to maintain the corpus luteum of pregnancy until the trophoblastic cells start secreting hormones.
COMPLICATIONS OF TREATMENT
The lack of agreement about dosage and timing is symptomatic of the complications which attend gonadotrophin therapy. These centre round overstimulation of the ovaries.
Superovulation and multiple pregnancy
The incidence of multiple pregnancy after gonadotrophin therapy is high. Gemzell & Roos (1966a) [Lancet Annotation, 1965) show two sets of twins (20%) in ten completed pregnancies. July 1965 saw the birth of quintuplets [Lancet Annotation, 1965; Liggins & Ibbertson, 1966) in New Zealand and Sweden. The former set survived and of the latter, delivered at 28 weeks, only one lived. A pregnancy with seven foetuses has been recorded and ended in abortion (Gemzell & Roos, 1966a (Neuwirth, Turksoy & Vande Wiele, 1965b) . No fatalities have been recorded with hpfsh. In the death reported by Mozes et al. (1965) hyperstimulation followed hmg-hcg therapy and was associated with vascular complications. In the days of pms and hcg two deaths were reported (Esteban-Altirriba, 1961 Bettendorf eí al., 1964; Buxton et al., 1963; Crooke et al., 1964a; Edwards, 1964; Gemzell & Roos, 1966a; Liggins & Ibbertson, 1966) . The largest series numbers forty-three (Gemzell & Roos, 1966a) . Between forty and fifty pregnancies after hmg-hcg have been reported (Buxton et al., 1963; Diczfalusy et al., 1964; Lunenfeld, 1963 Lunenfeld, , 1965 Lunenfeld et al., 1961 Lunenfeld et al., , 1962 Neuwirth, Todd, Turksoy & Vande Wiele, 1965a; Pasetto & Montanino, 1964a, b; Polishuik, Palti, Rabau, Lunenfeld & David, 1965) and the largest group of twenty is Vande Wiele's.
The problems of multiple pregnancy have already been mentioned. The frequent occurrence of bleeding in early pregnancy has been noted by some. There seems to be an increased incidence of abortion, the highest rate quoted being 50% (Vande Wiele & Turksoy, 1965) . In this clinic, this complication was usually associated with multiple pregnancy and occurred in the second trimester. Rupture of an ovarian 'hyperstimulation cyst' in early pregnancy has been seen (Pasetto & Montanino, 1964b ). This patient miscarried at 7 weeks, 9 days after a laparotomy and bilateral ovarian cystectomy. Placental insufficiency appears to be a feature of one series (Edwards, 1964; Crooke et al., 1964a) . One case of ectopie pregnancy following hpfsh-hcg occurred recently in Sweden.
The only foetal abnormality is recorded by Crooke et al. (1964a) . A macerated stillborn male foetus (one of binovular twins) showed a small lumbar spina bifida and an unusually broad and high bridge of nose. In this clinic all infants born, as well as most foetuses from abortions, have been examined and no con¬ genital malformation has as yet been noted. The first two patients treated successfully were both delivered of twins in January 1960 and none of the four children, now 6 years old, shows any sign of mental or physical defect. It is encouraging to note that animal experiments with induced ovulation seem to reveal no abnormality in the maturation of oocytes (Hafez & Ishibashi, 1964 (Zondek, 1931) .
